Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: LT2011 who wrote (11683)	11/23/2012 9:43:56 AM
From: NTTG	1 Recommendation Read Replies (1) \| Respond to of 13111

Not sure there is much of a case here... MGT compensation and performance have been a matter of public record for years. Unless MGT dropped the ball on a potential partner or co-development deal I do not understand the basis of the claim.....seems like a frivolous suit by an inexperienced investor for whom the failed IPO was the last straw, they will not be satisfied by the outcome...... much of the potential cash settlement goes to attorneys, have to assume he/she /they have sizable losses change in mgt is unlikely, moving S Orlow or C Eagle up the ladder probably will not help, who would be recruitable form the outside? change in compensation is too late to mean anything quick sale will be at market valuation, most longs loose. On the other hand, this may be the first wave of vultures starting to circle PVCT for a pending meal on the remaining cash and shelf...MGT does have experience wrapping up old companies (PDT) and rolling them into the next company when barriers get too big.